Compare CNXN & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNXN | AGIO |
|---|---|---|
| Founded | 1982 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 1998 | 2013 |
| Metric | CNXN | AGIO |
|---|---|---|
| Price | $58.55 | $28.39 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $36.25 |
| AVG Volume (30 Days) | 80.6K | ★ 1.6M |
| Earning Date | 02-04-2026 | 02-12-2026 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.24 | N/A |
| Revenue | ★ $2,878,704,000.00 | $44,791,000.00 |
| Revenue This Year | $5.85 | $28.75 |
| Revenue Next Year | $4.52 | $139.45 |
| P/E Ratio | $18.02 | ★ N/A |
| Revenue Growth | 3.19 | ★ 36.26 |
| 52 Week Low | $54.97 | $22.24 |
| 52 Week High | $74.84 | $46.00 |
| Indicator | CNXN | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 46.78 | 50.27 |
| Support Level | $56.53 | $26.54 |
| Resistance Level | $58.95 | $29.44 |
| Average True Range (ATR) | 1.25 | 1.07 |
| MACD | -0.11 | 0.58 |
| Stochastic Oscillator | 44.93 | 71.60 |
PC Connection Inc is a provider of information technology solutions. It provides products such as computer systems, software and peripheral equipment, networking communications, and other products and accessories that company purchase from manufacturers and distributors. The company also offers services involving design, configuration, and implementation of IT solutions. It conducts business operations through three business segments namely Connection Business Solutions, Connection Enterprise Solutions, and Connection Public Sector Solutions. The company generates maximum revenue Connection Enterprise Solutions segment.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.